Understanding Hepatitis D and its impact on patients
D-SOLVE Cohorts (Cohort a and B)
Hannover Medical School · NCT06160635
This study is trying to understand how Hepatitis D affects patients by looking at their backgrounds and health to help create better treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hannover Medical School (other) |
| Locations | 4 sites (Hanover and 3 other locations) |
| Trial ID | NCT06160635 on ClinicalTrials.gov |
What this trial studies
The D-SOLVE cohorts aim to comprehensively analyze a large group of patients infected with Hepatitis D virus (HDV) to identify key demographic, clinical, and immunological factors that influence disease outcomes. This multicenter observational study will collect both retrospective and prospective data from 750 HDV patients across four European centers. The goal is to enhance personalized treatment strategies and improve patient management by understanding the individual host responses to HDV infection. Additionally, the study will focus on identifying biomarkers that could predict treatment responses and disease progression.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are anti-HDV positive.
Not a fit: Patients who are anti-HDV negative will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment approaches for patients with Hepatitis D, improving their quality of life and reducing the burden of the disease.
How similar studies have performed: Other studies have shown success in understanding viral hepatitis through cohort analyses, making this approach promising yet still innovative in the context of HDV.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Anti-HDV positive * ≥18 years old * Sex: m/f/d * Informed consent for prospective procedures Exclusion Criteria: * Anti-HDV negative
Where this trial is running
Hanover and 3 other locations
- Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology — Hanover, Germany (RECRUITING)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (University of Milan) — Milan, Italy (NOT_YET_RECRUITING)
- Institutul de Boli Infectioase "Prof. Dr. Matei Bals" — Bucharest, Romania (RECRUITING)
- Karolinska University Hospital and Karolinska Institutet — Stockholm, Sweden (RECRUITING)
Study contacts
- Principal investigator: Markus Cornberg — Hannover Medical School
- Study coordinator: Petra Dörge
- Email: doerge.petra@mh-hannover.de
- Phone: +495115326057
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HDV, HDV Infection, Chronic Liver Disease, Hepatitis Delta, chronic liver disease, patient cohort, biomarker